US20130310318A1 - Skin collagen production-promoting agent - Google Patents

Skin collagen production-promoting agent Download PDF

Info

Publication number
US20130310318A1
US20130310318A1 US13/982,012 US201213982012A US2013310318A1 US 20130310318 A1 US20130310318 A1 US 20130310318A1 US 201213982012 A US201213982012 A US 201213982012A US 2013310318 A1 US2013310318 A1 US 2013310318A1
Authority
US
United States
Prior art keywords
tgf
collagen production
skin
promoting
skin collagen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/982,012
Other languages
English (en)
Inventor
Hiroshi Ueno
Yoshikazu Morita
Aiko Ono
Ken Katoh
Noriko Ueda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Megmilk Snow Brand Co Ltd
Original Assignee
Megmilk Snow Brand Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Megmilk Snow Brand Co Ltd filed Critical Megmilk Snow Brand Co Ltd
Assigned to MEGMILK SNOW BRAND CO., LTD., reassignment MEGMILK SNOW BRAND CO., LTD., ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ONO, AIKO, KATOH, KEN, MORITA, YOSHIKAZU, UEDA, NORIKO, UENO, HIROSHI
Publication of US20130310318A1 publication Critical patent/US20130310318A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A23L1/305—
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A23L2/66—Proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures
    • A61K2800/592—Mixtures of compounds complementing their respective functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients

Definitions

  • the present invention relates to a skin collagen production-promoting agent, a skin collagen production-promoting food or drink product, and a skin collagen production-promoting cosmetic product useful for preventing skin deterioration such as roughening, wrinkles, and the loss of elasticity in the skin.
  • a skin collagen production-promoting agent comprising transforming growth factor-beta (TGF- ⁇ ) and/or a TGF- ⁇ degradation product acquired by degrading TGF- ⁇ with a protease as an active ingredient.
  • TGF- ⁇ transforming growth factor-beta
  • collagen can hold water in molecules thereof and thereby helps to keep the skin moisturized, if collagen is destroyed by an external factor, the skin is dried and roughened. From the above, a skin collagen production-promoting agent is desired that can prevent wrinkles and sagging of the skin by promoting the biosynthesis of collagen, which is one of the major components of the dermic layer, without safety problems.
  • TGF- ⁇ Transforming growth factor beta
  • the TGF- ⁇ family includes five subtypes, which are proteins forming a dimer of about 25 kDa by disulfide bonds.
  • the TGF- ⁇ family has a function of regulating the promotion/inhibition of cell proliferation, biosynthesis, differentiation, and apoptosis. The effect of inducing differentiation in animal cells has been confirmed as a useful effect of TGF- ⁇ (Patent Document 1). TGF- ⁇ is also reported as a growth factor of fibroblast cells in the skin (Non-Patent Literature 1).
  • Patent Document 1 Japanese Laid-Open Patent Publication No. 2004-254674
  • Non-Patent Literature 1 J. Dermatol. Sci., Vol. 24 (Supple), p. 70, 2000
  • a problem of the present invention is to provide a skin collagen production-promoting agent without safety problems.
  • Another problem of the present invention is to provide a skin collagen production-promoting food or drink product and a skin collagen production-promoting cosmetic product containing such a substance.
  • TGF- ⁇ or a TGF- ⁇ degradation product acquired by degrading TGF- ⁇ increases collagen content in the skin, thereby completing the present invention.
  • the present invention includes the following embodiments.
  • a skin collagen production-promoting agent comprising TGF- ⁇ and/or a TGF- ⁇ degradation product as an active ingredient.
  • protease is one or more selected from trypsin, pancreatin, chymotrypsin, pepsin, papain, kallikrein, cathepsin, thermolysin, and V8 protease.
  • a skin collagen production-promoting food or drink product comprising the TGF- ⁇ and/or the TGF- ⁇ degradation product of any one of (1) to (4).
  • a skin collagen production-promoting cosmetic product comprising the TGF- ⁇ and/or the TGF- ⁇ degradation product of any one of (1) to (4).
  • a method of improving skin quality by oral ingestion of or application of TGF- ⁇ and/or a TGF- ⁇ degradation product is provided.
  • a method of promoting production of collagen in the skin comprising administering TGF- ⁇ and/or a TGF- ⁇ degradation product.
  • protease is one or more selected from trypsin, pancreatin, chymotrypsin, pepsin, papain, kallikrein, cathepsin, thermolysin, and V8 protease.
  • a method of preventing or improving skin deterioration comprising administering TGF- ⁇ and/or a TGF- ⁇ degradation product.
  • protease is one or more selected from trypsin, pancreatin, chymotrypsin, pepsin, papain, kallikrein, cathepsin, thermolysin, and V8 protease.
  • a skin deterioration-preventing or -improving agent comprising TGF- ⁇ and/or a TGF- ⁇ degradation product as an active ingredient.
  • protease is one or more selected from trypsin, pancreatin, chymotrypsin, pepsin, papain, kallikrein, cathepsin, thermolysin, and V8 protease.
  • a skin deterioration-preventing or -improving food or drink product comprising the TGF- ⁇ and/or the TGF- ⁇ degradation product of any one of (17) to (20).
  • a skin deterioration-preventing or -improving cosmetic product comprising the TGF- ⁇ and/or the TGF- ⁇ degradation product of any one of (17) to (20).
  • the present invention provides a skin collagen production-promoting agent, a skin collagen production-promoting food or drink product, and a skin collagen production-promoting cosmetic product containing TGF- ⁇ and/or a TGF- ⁇ degradation product as an active ingredient.
  • the skin collagen production-promoting agent, the skin collagen production-promoting food or drink product, and the skin collagen production-promoting cosmetic product have an effect of promoting collagen production in the skin and are useful for the prevention and treatment of wrinkles, sagging, feeling of dryness, and roughening of the skin.
  • a feature of the skin collagen production-promoting agent of the present invention is that TGF- ⁇ and/or a TGF- ⁇ degradation product acquired by degrading TGF- ⁇ with a protease is contained as an active ingredient.
  • TGF- ⁇ of any origin is usable in the present invention.
  • human- and bovine-derived TGF- ⁇ s have gene sequences already revealed and can be produced with gene recombination, and TGF- ⁇ produced with a genetic engineering technique is usable in the present invention.
  • TGF- ⁇ is contained in a relatively large amount in bovine colostrum and may be collected from the milk.
  • TGF- ⁇ is also collectable from the medium of cell culture and such cell-derived TGF- ⁇ is also usable.
  • milk-derived TGF- ⁇ is producible in accordance with a known method (see, e.g., J. Protein Chem., Vol. 10, pp. 565-575, 1991), and TGF- ⁇ can be acquired from raw milk, powdered milk, skim milk, reconstituted milk, or other processed milk by heat treatment, salting treatment, ethanol treatment, various chromatographic processes such as ion exchange chromatography and gel filtration chromatography, and an ultrafiltration process in a combined manner as needed.
  • a peptide mixture is usable that is acquired by limited proteolysis of TGF- ⁇ with a protease such as trypsin, pancreatin, chymotrypsin, pepsin, papain, kallikrein, cathepsin, thermolysin, and V8 protease to an average molecular weight of 8,000 or less. Meanwhile, the lower limit of the average molecular weight is preferably equal to or greater than 500.
  • the average molecular weight of the TGF- ⁇ degradation product is 500 or more and 8000 or less, 1500 or more and 8000 or less, 2500 or more and 8000 or less, 3500 or more and 8000 or less, 4500 or more and 8000 or less, 5500 or more and 8000 or less, 6500 or more and 8000 or less, 7500 or more and 8000 or less, 500 or more and 7500 or less, 1500 or more and 7500 or less, 2500 or more and 7500 or less, 3500 or more and 7500 or less, 4500 or more and 7500 or less, 5500 or more and 7500 or less, 6500 or more and 7500 or less, 500 or more and 6500 or less, 1500 or more and 6500 or less, 2500 or more and 6500 or less, 3500 or more and 6500 or less, 4500 or more and 6500 or less, 5500 or more and 6500 or less, 500 or more and 5500 or less, 1500 or more and 5500 or less, 2500 or more and 5500 or less, 3500 or more and 6500
  • the skin collagen production-promoting agent of the present invention is orally administered or applied to produce the skin collagen production-promoting effect.
  • the active ingredient i.e., TGF- ⁇ or a TGF- ⁇ degradation product
  • the active ingredient i.e., TGF- ⁇ or a TGF- ⁇ degradation product
  • the active ingredient i.e., TGF- ⁇ or a TGF- ⁇ degradation product
  • the active ingredient i.e., TGF- ⁇ or a TGF- ⁇ degradation product
  • an oral agent such as powders, granules, tablets, capsules, and drinkable preparations.
  • oral agents such as powders, granules, tablets, and capsules are formulated in a usual manner by using excipients such as starch, lactose, sucrose, mannitol, carboxymethylcellulose, corn starch, and inorganic salts.
  • binding agents include, for example, starch, dextrin, gum arabic, gelatin, hydroxypropyl starch, sodium carboxymethyl cellulose, methylcellulose, crystalline cellulose, ethyl cellulose, and polyvinyl pyrrolidone.
  • Disintegrating agents include, for example, starch, hydroxypropyl starch, carboxymethyl cellulose, sodium carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose, and crystalline cellulose.
  • Surfactants include soybean lecithin, sucrose fatty acid ester, etc.; lubricants include talc, wax, sucrose fatty acid ester, hydrogenated vegetable oil, etc.; and fluidity promoters include anhydrous silicic acid, dried aluminum hydroxide, magnesium silicate, etc.
  • TGF- ⁇ or a TGF- ⁇ degradation product may be combined with nutrients, food or drink etc., directly or after formulated into preparations. If TGF- ⁇ or a TGF- ⁇ degradation product is contained together with a component conventionally considered to be effective in collagen production, such as vitamin C, a further skin collagen production-promoting effect can be expected. Since TGF- ⁇ or a TGF- ⁇ degradation product is relatively stable to heat, raw materials containing TGF- ⁇ or a TGF- ⁇ degradation product can be heat-sterilized under the normally used conditions.
  • the skin collagen production-promoting agent of the present invention can be combined with known normally used components depending on the purpose of use and prepared as various dosage forms such as liquid formulation, solid formulation, and semisolid formulation and preferable compositions include ointment, gel, cream, spray, patches, lotion, powder, etc.
  • the skin collagen production-promoting agent of the present invention can be mixed with hydrocarbons such as vaseline, stearyl alcohol, higher fatty acid lower alkyl ester such as isopropyl myristate, animal oil and fat such as lanolin, polyhydric alcohol such as glycerin, glycerin fatty acid ester, mono-stearic acid, surfactants such as polyethylene glycol, inorganic salt, wax, resin, water, and, if needed, preservatives such as methyl parahydroxybenzoate and butyl parahydroxybenzoate, so as to produce skin collagen production-promoting cosmetics and pharmaceutical agents.
  • hydrocarbons such as vaseline, stearyl alcohol, higher fatty acid lower alkyl ester such as isopropyl myristate, animal oil and fat such as lanolin
  • polyhydric alcohol such as glycerin, glycerin fatty acid ester, mono-stearic acid
  • surfactants such as polyethylene glycol, inorganic salt, wax, resin
  • an effective oral administration dose of the skin collagen production-promoting agent of the present invention is not constant and is prescribed as needed depending on the drug formulation, the administration method, the purpose of use, and the age, body weight, and disease condition of the patient to which the promoter is administered, it was found as a result of animal experiments using rats that the skin collagen production-promoting effect can be expected to be produced by ingesting 10 ⁇ g per one kilogram of rat body weight or more of TGF- ⁇ and/or a TGF- ⁇ degradation product.
  • the effect can be expected by ingesting 10 ⁇ g per adult human or more of TGF- ⁇ and/or a TGF- ⁇ degradation product daily and, thus, TGF- ⁇ and/or a TGF- ⁇ degradation product may be combined with food or drink or administered as a medical drug so that this required amount can be ensured.
  • the administration can be performed several times per day in a divided manner as needed.
  • TGF- ⁇ and/or a TGF- ⁇ degradation product may preferably be contained to be 0.001 to 2 wt % based on the total dosage of the composition to be applied. However, if the composition is diluted upon use as in the case of bath additives, the contained amount may further be increased.
  • TGF- ⁇ degradation products B, C, and D were acquired by lyophilization.
  • the average molecular weights of the TGF- ⁇ degradation products B, C, and D acquired in this manner were about 8,000, about 500, and about 300, respectively.
  • the fractions B and C are directly usable as the skin collagen production-promoting agent.
  • control group a group administered 10 ⁇ g per one kilogram of rat body weight of the fraction A acquired in Example 1
  • A-2 group a group administered 100
  • TGF- ⁇ and a TGF- ⁇ degradation product having an average molecular weight of 500 or more and 8,000 or less have the skin collagen production-promoting effect and are useful as a skin collagen production-promoting agent. It was also clarified that the skin collagen production-promoting effect is observed when TGF- ⁇ and a TGF- ⁇ degradation product are administered in an amount of at least 10 ⁇ g per one kilogram of rat body weight.
  • the collagen production-promoting effects of the fraction A acquired in Example 1 and the fraction B acquired in Example 2 were examined by experiments using a human fibroblast cell line [CCD45SK (ATCCRL 1506) collected from the skin of Caucasian women].
  • the normal human fibroblast cell line was seeded onto a 24-well plate at 4 ⁇ 10 4 cells/well/0.4 ml by using a modified Eagle's medium (MEM, 10-101, Dainippon Pharmaceutical Co., Ltd.) containing 10 vol % fetal bovine serum (hereinafter abbreviated as FBS), cultured with 5% carbon dioxide under saturated water vapor at 37° C. for 24 hours, and then replaced to a 0.6 vol % FBS-containing MEM medium.
  • MEM modified Eagle's medium
  • FBS fetal bovine serum
  • TGF- ⁇ and a TGF- ⁇ degradation product have an effect on the skin fibroblast cells to promote collagen production and are useful as a skin collagen production-promoting agent.
  • Skin collagen production-promoting drink having composition shown in Table 3 was manufactured in a usual manner. Flavor of the manufactured drink was favorable and did not deteriorate after storage for one year at room temperature, and there was no problem such as precipitation.
  • Dough having composition shown in Table 4 was prepared, shaped, and baked in a usual manner to manufacture skin collagen production-promoting biscuits.
  • Skin collagen production-promoting agent having composition shown in Table 5 was manufactured in a usual manner.
  • Skin lotion having composition shown in Table 6 was manufactured in a usual manner.
  • Cream having composition shown in Table 7 was manufactured in a usual manner.
  • the skin lotion acquired in Example 6 and the cream acquired in Example 7 were used for a practical use test. Comparison products were used that had the same compositions as Examples 6 and 7 except that TGF- ⁇ and the TGF- ⁇ degradation product were removed. Twenty adult women having dry skin with sagging and fine wrinkles recognized on the facial surfaces were randomly divided into two groups of 10 each (groups E and F) and twenty women with roughening of skin recognized on the hands were randomly divided into two groups of 10 each (groups G and H) to apply 2 g of the skin lotion of the preset invention to the facial surfaces of the group E, 2 g of the skin lotion of the comparison product to the facial surfaces of the group F, 2 g of the cream of the preset invention to the fingers of the group and 2 g of the cream of the comparison product to the fingers of the group H, twice a day in a similar manner to the normal usage condition for 10 days. The results are shown in Table 8.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Birds (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Non-Alcoholic Beverages (AREA)
US13/982,012 2011-02-09 2012-02-07 Skin collagen production-promoting agent Abandoned US20130310318A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011026446A JP5890100B2 (ja) 2011-02-09 2011-02-09 皮膚コラーゲン産生促進剤
JP2011-026446 2011-02-09
PCT/JP2012/052690 WO2012108410A1 (fr) 2011-02-09 2012-02-07 Activateur de production de collagène cutané

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2012/052690 A-371-Of-International WO2012108410A1 (fr) 2011-02-09 2012-02-07 Activateur de production de collagène cutané

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/863,477 Division US9763868B2 (en) 2011-02-09 2015-09-24 Skin collagen production-promoting agent

Publications (1)

Publication Number Publication Date
US20130310318A1 true US20130310318A1 (en) 2013-11-21

Family

ID=46638623

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/982,012 Abandoned US20130310318A1 (en) 2011-02-09 2012-02-07 Skin collagen production-promoting agent
US14/863,477 Active US9763868B2 (en) 2011-02-09 2015-09-24 Skin collagen production-promoting agent

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/863,477 Active US9763868B2 (en) 2011-02-09 2015-09-24 Skin collagen production-promoting agent

Country Status (11)

Country Link
US (2) US20130310318A1 (fr)
EP (1) EP2674163B1 (fr)
JP (1) JP5890100B2 (fr)
KR (1) KR101705938B1 (fr)
CN (1) CN103347531B (fr)
AU (1) AU2012215805B2 (fr)
CA (1) CA2824746C (fr)
HK (1) HK1191546A1 (fr)
MY (1) MY161419A (fr)
TW (1) TWI531382B (fr)
WO (1) WO2012108410A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9255123B2 (en) 2011-03-10 2016-02-09 Megmilk Snow Brand Co., Ltd. Skin-beautifying agent
US9763868B2 (en) 2011-02-09 2017-09-19 Megmilk Snow Brand Co., Ltd. Skin collagen production-promoting agent
US10016481B2 (en) 2011-10-04 2018-07-10 Megmilk Snow Brand Co., Ltd. Sensation-improving agent

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102021764B1 (ko) * 2013-05-03 2019-09-18 (주)아모레퍼시픽 진세노사이드 Rh4를 함유하는 피부 외용제 조성물
JP6332941B2 (ja) * 2013-11-01 2018-05-30 株式会社東洋発酵 美容健康用経口組成物
JP2016056116A (ja) * 2014-09-08 2016-04-21 株式会社ディーエイチシー コラーゲン産生促進用組成物
JP6874320B2 (ja) * 2015-10-21 2021-05-19 大正製薬株式会社 頭皮用剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3794722A (en) * 1968-11-20 1974-02-26 M Taya Iron composition for treating anemia
US20100183682A1 (en) * 2005-08-31 2010-07-22 Atsuhito Nakao Method of treating allergies using tgf-beta1 and allergens

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920002163B1 (ko) * 1988-08-05 1992-03-19 온코겐, 어 리미티드 파트너쉽 TGF-β를 이용한 건선 치료방법
DK0527283T3 (da) * 1991-08-12 1998-08-10 Nestle Sa Levnedsmiddelsammensætning
JPH0625288A (ja) * 1992-07-10 1994-02-01 Kuraray Co Ltd ペプチドまたはその塩
US5420243A (en) * 1993-01-26 1995-05-30 Celtrix Pharmaceuticals, Inc. Biologically active TGF-β2 peptides
US6974796B1 (en) * 1999-08-17 2005-12-13 Girsh Leonard S Therapeutic compositions for treatment of a damaged tissue
CA2296311A1 (fr) * 1999-01-28 2000-07-28 Universite Laval Hydrolysat enzymatique de proteines du lait
JP4291967B2 (ja) * 2001-11-08 2009-07-08 雪印乳業株式会社 皮膚コラーゲン産生促進剤
JP2004254674A (ja) 2003-02-25 2004-09-16 Mutsumi Takagi 動物細胞の分化誘導培養方法
ATE493966T1 (de) * 2003-05-07 2011-01-15 Snow Brand Milk Products Co Ltd Mittel zur förderung der hautkollagenproduktion
EP1604693A1 (fr) * 2004-06-09 2005-12-14 Scil Technology GmbH Support formé in situ, son procédé de préparation et son utilisation
CN101400787B (zh) 2006-01-27 2013-01-23 株式会社Prostemics 采用脂肪来源成体干细胞大量制造生长因子的方法
WO2007101130A2 (fr) 2006-02-23 2007-09-07 Novocell, Inc. Compositions et procédés utiles pour la culture de cellules différenciables
JP5274814B2 (ja) * 2007-03-13 2013-08-28 雪印メグミルク株式会社 美白剤
WO2010006412A1 (fr) * 2008-06-23 2010-01-21 Innovactiv Inc. Compositions cosmétiques comportant un fluide corporel d'étoile de mer et leurs procédés d'utilisation
US8247435B2 (en) * 2009-02-19 2012-08-21 Thornthwaite Jerry T Formulations for treating human and animal diseases
JP5955499B2 (ja) 2010-09-30 2016-07-20 雪印メグミルク株式会社 皮膚コラーゲン産生促進剤
JP2012077018A (ja) 2010-09-30 2012-04-19 Snow Brand Milk Products Co Ltd 皮膚コラーゲン産生促進剤
JP5890100B2 (ja) 2011-02-09 2016-03-22 雪印メグミルク株式会社 皮膚コラーゲン産生促進剤
JP2012188384A (ja) 2011-03-10 2012-10-04 Snow Brand Milk Products Co Ltd 美肌剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3794722A (en) * 1968-11-20 1974-02-26 M Taya Iron composition for treating anemia
US20100183682A1 (en) * 2005-08-31 2010-07-22 Atsuhito Nakao Method of treating allergies using tgf-beta1 and allergens

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Akpek G. Clinical grading in chronic graft-versus-host disease: is it time for change? Leuk Lymphoma. 2002 Jun;43(6):1211-20. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9763868B2 (en) 2011-02-09 2017-09-19 Megmilk Snow Brand Co., Ltd. Skin collagen production-promoting agent
US9255123B2 (en) 2011-03-10 2016-02-09 Megmilk Snow Brand Co., Ltd. Skin-beautifying agent
US10016481B2 (en) 2011-10-04 2018-07-10 Megmilk Snow Brand Co., Ltd. Sensation-improving agent

Also Published As

Publication number Publication date
AU2012215805B2 (en) 2016-07-28
KR20140020896A (ko) 2014-02-19
CA2824746A1 (fr) 2012-08-16
HK1191546A1 (zh) 2014-08-01
EP2674163A1 (fr) 2013-12-18
TW201309337A (zh) 2013-03-01
JP5890100B2 (ja) 2016-03-22
WO2012108410A1 (fr) 2012-08-16
CN103347531A (zh) 2013-10-09
TWI531382B (zh) 2016-05-01
CA2824746C (fr) 2019-01-15
AU2012215805A1 (en) 2013-08-15
EP2674163A4 (fr) 2015-02-11
KR101705938B1 (ko) 2017-02-10
NZ614185A (en) 2014-09-26
EP2674163B1 (fr) 2016-08-10
MY161419A (en) 2017-04-14
US9763868B2 (en) 2017-09-19
CN103347531B (zh) 2018-09-07
US20160015618A1 (en) 2016-01-21
JP2012167021A (ja) 2012-09-06

Similar Documents

Publication Publication Date Title
US9763868B2 (en) Skin collagen production-promoting agent
US20100035819A1 (en) Method of promoting skin collagen production
JP6259209B2 (ja) コラーゲン産生促進剤
JP6259207B2 (ja) エラスチン産生促進剤
JP5955499B2 (ja) 皮膚コラーゲン産生促進剤
JP4698935B2 (ja) 皮膚コラーゲン産生促進剤
KR101789355B1 (ko) 피부 콜라겐 생성 촉진제
TWI602581B (zh) 玻尿酸產生促進劑
JP4698934B2 (ja) 皮膚コラーゲン産生促進剤
NZ614185B2 (en) Skin collagen production promoter
WO2012043711A1 (fr) Agent favorisant la production du collagène de la peau
WO2012043713A1 (fr) Agent favorisant la production du collagène de la peau

Legal Events

Date Code Title Description
AS Assignment

Owner name: MEGMILK SNOW BRAND CO., LTD.,, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:UENO, HIROSHI;MORITA, YOSHIKAZU;ONO, AIKO;AND OTHERS;SIGNING DATES FROM 20130718 TO 20130720;REEL/FRAME:030884/0035

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION